Amarin Corporation PLC (NASDAQ:AMRN) – Analysts at SunTrust Banks decreased their FY2020 earnings per share estimates for Amarin Corporation PLC in a research report issued on Monday. SunTrust Banks analyst J. Boris now forecasts that the biopharmaceutical company will post earnings per share of $0.60 for the year, down from their prior forecast of $0.61.

Amarin Corporation PLC (NASDAQ:AMRN) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $47.10 million for the quarter, compared to analyst estimates of $45.85 million. The firm’s quarterly revenue was up 45.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.08) EPS.

TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/02/equities-analysts-issue-forecasts-for-amarin-corporation-plcs-fy2020-earnings-amrn.html.

AMRN has been the subject of a number of other reports. BidaskClub cut Amarin Corporation PLC from a “sell” rating to a “strong sell” rating in a report on Thursday, August 24th. Zacks Investment Research cut Amarin Corporation PLC from a “buy” rating to a “hold” rating in a report on Monday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a report on Wednesday, August 9th. ValuEngine raised Amarin Corporation PLC from a “sell” rating to a “hold” rating in a report on Thursday, August 31st. Finally, Cantor Fitzgerald set a $10.00 price objective on Amarin Corporation PLC and gave the stock a “buy” rating in a report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $7.75.

Several hedge funds have recently made changes to their positions in the company. Westside Investment Management Inc. increased its stake in shares of Amarin Corporation PLC by 1.1% in the 2nd quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 300 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Amarin Corporation PLC by 4.8% in the 1st quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 1,500 shares during the last quarter. State Street Corp increased its stake in shares of Amarin Corporation PLC by 1.3% in the 2nd quarter. State Street Corp now owns 201,995 shares of the biopharmaceutical company’s stock valued at $814,000 after acquiring an additional 2,640 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Amarin Corporation PLC by 0.9% in the 1st quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock valued at $1,266,000 after acquiring an additional 3,413 shares during the last quarter. Finally, Perkins Capital Management Inc. increased its stake in shares of Amarin Corporation PLC by 20.3% in the 2nd quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock valued at $167,000 after acquiring an additional 7,000 shares during the last quarter. 37.76% of the stock is owned by institutional investors.

In other news, insider Steven B. Ketchum sold 63,479 shares of the company’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $3.48, for a total value of $220,906.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.72% of the company’s stock.

Amarin Corporation PLC Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Earnings History and Estimates for Amarin Corporation PLC (NASDAQ:AMRN)

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.